{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T11:02:47Z","timestamp":1777633367468,"version":"3.51.4"},"reference-count":29,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T00:00:00Z","timestamp":1777420800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>This study aims to explore the association between cardiometabolic diseases (CMDs) involving diabetes and the risk of prostate cancer (PCa) as well as its mortality.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The population-based cohort, comprising 71, 566 participants, was derived from the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial. CMDs encompassed three conditions, namely diabetes, heart diseases, and stroke. Multivariable Cox proportional hazards and competing risk regression models were used to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) for assessing associations between individual diabetes, coexisting CMDs, and PCa incidence and mortality.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>At baseline, 12, 979 participants had at least one CMD, while 2, 391 had two or more concurrent CMDs. Over a 17-year mean follow-up, 8, 263 participants were diagnosed with PCa. Participants with baseline diabetes exhibited an 18% elevated risk of developing PCa compared with CMD-free counterparts (HR: 1.18, 95% CI: 1.08~1.29). Among participants with multimorbidity, only diabetes-heart disease comorbidity was significantly associated with an elevated risk of PCa incidence (HR: 1.31, 95% CI: 1.09~1.59). Neither diabetes, heart disease, nor stroke had a statistically significant association with PCa-specific mortality risk. However, compared with CMD-free individuals, those with a single type of CMD exhibited a significantly reduced risk of non-aggressive PCa-specific mortality (HR: 0.50, 95% CI: 0.26~0.99).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Baseline diabetes was independently associated with an increased incidence of PCa, and the comorbidity of diabetes with heart disease further amplified this risk. The presence of a single CMD reduced the risk of non-invasive PCa-specific mortality in affected individuals.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1799790","type":"journal-article","created":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T04:35:48Z","timestamp":1777437348000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Cardiometabolic comorbidities and prostate cancer risk: evidence from the prostate, lung, colorectal, and ovarian cancer screening trial"],"prefix":"10.3389","volume":"16","author":[{"given":"Qian","family":"Zhu","sequence":"first","affiliation":[{"name":"Key Laboratory of Cardiomyopathy and Heart Failure, Affiliated Hospital of Panzhihua University","place":["Sichuan, China"]},{"name":"Clinical Medical Research Center, Panzhihua Central Hospital","place":["Sichuan, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lan","family":"Zeng","sequence":"additional","affiliation":[{"name":"Department of Geriatric Medicine, Panzhihua Central Hospital","place":["Sichuan, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Menghui","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Geriatric Medicine, Panzhihua Central Hospital","place":["Sichuan, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,4,29]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.70.7794","article-title":"Effect of comorbidity on prostate cancer-specific mortality: a prospective observational study","volume":"35","author":"Rajan","year":"2017","journal-title":"J Clin Oncol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"47","DOI":"10.2147\/CLEP.S47153","article-title":"Comorbidity and survival of Danish prostate cancer patients from 2000-2011: a population-based cohort study","volume":"5","author":"Nguyen-Nielsen","year":"2013","journal-title":"Clin Epidemiol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21342","article-title":"The impact of comorbidity on cancer and its treatment","volume":"66","author":"Sarfati","year":"2016","journal-title":"CA Cancer J Clin"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.18865\/ed.30.S1.185","article-title":"Co-morbidities in a retrospective cohort of prostate cancer patients","volume":"30","author":"Jefferson","year":"2020","journal-title":"Ethn Dis"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1007\/s00345-016-1963-7","article-title":"Comorbidity and age cannot explain variation in life expectancy associated with treatment of non-metastatic prostate cancer","volume":"35","author":"Boehm","year":"2017","journal-title":"World J Urol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/s41391-021-00467-5","article-title":"Estimating patient health in prostate cancer treatment counseling","volume":"26","author":"Chesnut","year":"2023","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaccao.2023.01.010","article-title":"Risk of cancer after diagnosis of cardiovascular disease","volume":"5","author":"Bell","year":"2023","journal-title":"JACC CardioOncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.18632\/aging.205886","article-title":"The association between diabetes mellitus and prostate cancer: a meta-analysis and Mendelian randomization","volume":"16","author":"Ye","year":"2024","journal-title":"Aging (Albany NY)"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1002\/dmrr.2582","article-title":"Diabetes mellitus is associated with elevated risk of mortality amongst patients with prostate cancer: a meta-analysis of 11 cohort studies","volume":"31","author":"Cai","year":"2015","journal-title":"Diabetes Metab Res Rev"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1007\/s00592-012-0439-5","article-title":"Diabetes mellitus and risk of prostate cancer: an updated meta-analysis based on 12 case-control and 25 cohort studies","author":"Zhang","year":"2012","journal-title":"Acta Diabetol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.7314\/apjcp.2012.13.8.4097","article-title":"Diabetes mellitus and prostate cancer risk in Asian countries: a meta-analysis","volume":"13","author":"Long","year":"2012","journal-title":"Asian Pac J Cancer Prev"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0336980","article-title":"The mediating role of blood metabolites in the association between myocardial infarction and cancer risk: an observational and mendelian randomization analysis","volume":"20","author":"Zhu","year":"2025","journal-title":"PloS One"},{"key":"B14","doi-asserted-by":"publisher","first-page":"273S","DOI":"10.1016\/s0197-2456(00)00098-2","article-title":"Design of the prostate, lung, colorectal and ovarian (PLCO) cancer screening trial","volume":"21","author":"Prorok","year":"2000","journal-title":"Control Clin Trials"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2017.00097","article-title":"Glucose metabolism in the progression of prostate cancer","volume":"8","author":"Cutruzzol\u00e0","year":"2017","journal-title":"Front Physiol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1111\/obr.12674","article-title":"Glucose impairments and insulin resistance in prostate cancer: the role of obesity, nutrition and exercise","volume":"19","author":"Di Sebastiano","year":"2018","journal-title":"Obes Rev"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/s41391-024-00809-z","article-title":"Hyperglycemia and microRNAs in prostate cancer","volume":"28","author":"Russo","year":"2025","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajpath.2025.08.011","article-title":"Stromal steroid 5 alpha-reductase 2 promotes prostate growth through WNT5A-lymphoid enhancer-binding factor 1-insulin-like growth factor 1 signaling in benign prostatic hyperplasia","volume":"195","author":"Sharkey","year":"2025","journal-title":"Am J Pathol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3390\/antiox14121517","article-title":"Exploiting oxidative stress as Achilles\u2019 heel: from redox homeostasis to ferroptosis in prostate cancer","volume":"14","author":"Yu","year":"2025","journal-title":"Antioxidants (Basel)"},{"key":"B20","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1111\/j.1365-2559.2011.04033.x","article-title":"Prostate cancer and inflammation: the evidence","volume":"60","author":"Sfanos","year":"2012","journal-title":"Histopathology"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2011-0321","article-title":"Changes in biomarkers of inflammation and angiogenesis during androgen deprivation therapy for prostate cancer","volume":"17","author":"Saylor","year":"2012","journal-title":"Oncologist"},{"key":"B22","doi-asserted-by":"publisher","first-page":"11339","DOI":"10.1038\/s41467-025-67856-5","article-title":"Prostate cancer cells converge to an inflammatory-like state upon metastatic dissemination","volume":"16","author":"Keshavarzian","year":"2025","journal-title":"Nat\u00a0Commun"},{"key":"B23","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1038\/s41467-025-67510-0","article-title":"Multiomics insight into disease trajectories of cardiometabolic diseases and cancer","volume":"17","author":"Jiang","year":"2025","journal-title":"Nat Commun"},{"key":"B24","doi-asserted-by":"publisher","first-page":"2218","DOI":"10.1038\/s41598-018-38285-w","article-title":"The effect of metformin therapy on incidence and prognosis in prostate cancer: a systematic review and meta-analysis","volume":"9","author":"He","year":"2019","journal-title":"Sci Rep"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2017.417","article-title":"Metformin reverses prostate cancer resistance to enzalutamide by targeting TGF-\u03b21\/STAT3 axis-regulated EMT","volume":"8","author":"Liu","year":"2017","journal-title":"Cell Death Dis"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1002\/pros.23000","article-title":"Metformin\u00a0represses androgen-dependent and androgen-independent prostate cancers\u00a0by targeting androgen receptor","volume":"75","author":"Wang","year":"2015","journal-title":"Prostate"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2017.01.044","article-title":"Regular aspirin use and the risk of lethal prostate cancer in the Physicians\u2019 Health Study","volume":"72","author":"Downer","year":"2017","journal-title":"Eur Urol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-2235","article-title":"Aspirin, NSAIDs, and risk of prostate cancer: results from the REDUCE study","volume":"21","author":"Vidal","year":"2015","journal-title":"Clin Cancer Res"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9082680","article-title":"Application of anti-inflammatory agents in prostate cancer","volume":"9","author":"Hatano","year":"2020","journal-title":"J Clin Med"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1799790\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T04:35:57Z","timestamp":1777437357000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1799790\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,29]]},"references-count":29,"alternative-id":["10.3389\/fonc.2026.1799790"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1799790","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,29]]},"article-number":"1799790"}}